Two independent research projects have found that GLP1 agonists dramatically improve the level of endogenous insulin production in Type 1 Diabetic patients.
GLP1 Agonists are currently approved for Type 2 Diabetes but not Type 1.
I would like to shine some light on this work. Please see “Semaglutide in Early Type1 Diabetes . . . .”, in the NEJM. The researcher is Dr, Paresh Dandona.
The other research project is being led by Dr. Andrew Stewart at Mt Sinai. There is an excellent video (and several articles) on Regeneration of Pancreatic Beta Cells.
I am a pre-diabetic Type 1 and, thanks to what I have learned here I have sourced Rybelsus and started taking it along with Harmine. I cannot wait for official approval – and feel less crazy about having gone off the reservation, surrounded by all the folks taking Rapamycin. But I would love to see GLP1 agonists approved for Type 1 so that I might have a shot at getting it paid for through “official” channels.
This could be a very big deal for Type 1 diabetes. Spread the word . . .
This was in the “correspondence” section, and so, I assume, an unpublished study of 10 patients. By taking 0.5mg wekly of Semaglutide:
Prandial insulin was eliminated in all the patients within 3 months, and basal insulin was eliminated in 7 patients within 6 months.
while HbA1c went from 11.7 soon after diagnosis to 5.7 twelve months later, and c-peptide, a proxy for insulin production, rose substantially. Really remarkable.
I was pretty happy with Tirzepatide and our year of losing weight.
I’m amazed at how much more effective Retatrutide is over Tz…
The added GCGR aspect that actually burns fat makes a huge difference. Tz and Sema do not “burn” fat, they do inhibit appetite, control glucose and slow digestion, the weight loss is due to caloric reduction and the glucose control. With RT you have the added effect of stimulating beige and brown fat to boost whole-body thermogenic capacity.
